These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 22265843)

  • 21. Optical diagnostics studies of air flow and powder fluidisation in Nexthaler®. Part II: Use of fluorescent imaging to characterise transient release of fines from a dry powder inhaler.
    Merusi C; Brambilla G; Long EJ; Hargrave GK; Versteeg HK
    Int J Pharm; 2018 Oct; 549(1-2):96-108. PubMed ID: 30017819
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of Device Design and Formulation on the In Vitro Comparability for Multi-Unit Dose Dry Powder Inhalers.
    Shur J; Saluja B; Lee S; Tibbatts J; Price R
    AAPS J; 2015 Sep; 17(5):1105-16. PubMed ID: 25956383
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Highly loaded interactive mixtures for dry powder inhalers: prediction of the adhesion capacity using surface energy and solubility parameters.
    Wagner KG; Dowe U; Zadnik J
    Pharmazie; 2005 May; 60(5):339-44. PubMed ID: 15918581
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A proposed definition of the 'activity' of surface sites on lactose carriers for dry powder inhalation.
    Grasmeijer F; Frijlink HW; de Boer AH
    Eur J Pharm Sci; 2014 Jun; 56():102-4. PubMed ID: 24613490
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The influence of physical properties and morphology of crystallised lactose on delivery of salbutamol sulphate from dry powder inhalers.
    Kaialy W; Martin GP; Larhrib H; Ticehurst MD; Kolosionek E; Nokhodchi A
    Colloids Surf B Biointerfaces; 2012 Jan; 89():29-39. PubMed ID: 21962946
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Understanding the effect of lactose particle size on the properties of DPI formulations using experimental design.
    Guenette E; Barrett A; Kraus D; Brody R; Harding L; Magee G
    Int J Pharm; 2009 Oct; 380(1-2):80-8. PubMed ID: 19596428
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of recrystallized lactose as carrier for inhalation powder of interferon a2b.
    Jiang RG; Pan WS; Wang CL; Liu H
    Pharmazie; 2005 Aug; 60(8):632-3. PubMed ID: 16124411
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of a Rational Design Space for Optimizing Mixing Conditions for Formation of Adhesive Mixtures for Dry-Powder Inhaler Formulations.
    Sarkar S; Minatovicz B; Thalberg K; Chaudhuri B
    J Pharm Sci; 2017 Jan; 106(1):129-139. PubMed ID: 27546350
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The relationship between drug concentration, mixing time, blending order and ternary dry powder inhalation performance.
    Jones MD; Santo JG; Yakub B; Dennison M; Master H; Buckton G
    Int J Pharm; 2010 May; 391(1-2):137-47. PubMed ID: 20211715
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Determination of the polar and total surface energy distributions of particulates by inverse gas chromatography.
    Das SC; Larson I; Morton DA; Stewart PJ
    Langmuir; 2011 Jan; 27(2):521-3. PubMed ID: 21174410
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aerosolisation of beclomethasone dipropionate using spray dried lactose/polyethylene glycol carriers.
    Gilani K; Rouholamini Najafabadi A; Barghi M; Rafiee-Tehrani M
    Eur J Pharm Biopharm; 2004 Nov; 58(3):595-606. PubMed ID: 15451534
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of milling and sieving on functionality of dry powder inhalation products.
    Steckel H; Markefka P; teWierik H; Kammelar R
    Int J Pharm; 2006 Feb; 309(1-2):51-9. PubMed ID: 16377105
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers.
    Zeng XM; MacRitchie HB; Marriott C; Martin GP
    Int J Pharm; 2007 Mar; 333(1-2):45-55. PubMed ID: 17064863
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The influence of drug loading on formulation structure and aerosol performance in carrier based dry powder inhalers.
    Young PM; Wood O; Ooi J; Traini D
    Int J Pharm; 2011 Sep; 416(1):129-35. PubMed ID: 21708238
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of particle morphology on the triboelectrification in dry powder inhalers.
    Murtomaa M; Mellin V; Harjunen P; Lankinen T; Laine E; Lehto VP
    Int J Pharm; 2004 Sep; 282(1-2):107-14. PubMed ID: 15336386
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of surface energy distributions by inverse gas chromatography to understand mechanofusion processing and functionality of lactose coated with magnesium stearate.
    Das SC; Zhou Q; Morton DA; Larson I; Stewart PJ
    Eur J Pharm Sci; 2011 Jul; 43(4):325-33. PubMed ID: 21621612
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An evaluation of the acidogenic potential of asthma inhalers.
    Tootla R; Toumba KJ; Duggal MS
    Arch Oral Biol; 2004 Apr; 49(4):275-83. PubMed ID: 15003546
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of inverse gas chromatography measurement conditions on surface energy parameters of lactose monohydrate.
    Planinsek O; Zadnik J; Rozman S; Kunaver M; Dreu R; Srcic S
    Int J Pharm; 2003 Apr; 256(1-2):17-23. PubMed ID: 12695007
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [A novel pulmonary delivery system--dry powder inhalers].
    Tang Y; Zhu JB; Chen XJ
    Yao Xue Xue Bao; 2009 Jun; 44(6):571-4. PubMed ID: 19806884
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preparation and characterization of physically modified glass beads used as model carriers in dry powder inhalers.
    Zellnitz S; Redlinger-Pohn JD; Kappl M; Schroettner H; Urbanetz NA
    Int J Pharm; 2013 Apr; 447(1-2):132-8. PubMed ID: 23470233
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.